Price History

Hover for the daily close. The dotted line marks the period open.

Compare NRXS with… →

NRXS Key Statistics

As of Sep 4, 2026

Trading

Open: $6.01
Previous Close: $6.07
Day's Range: 5.94–6.08
52-Week Range: 2.21–9.33
Volume: 47.20K
Beta: 1.45

Valuation

Market Cap: $74.84M
P/E Ratio: unprofitable
P/S ratio: 14.08
EPS (ttm): −0.76

Financials (FY)

Revenue (FY): $3.57M+32.89%
Net Income (FY): −$7.80M
Profit margin: −144.44%
Shares Outstanding: 12.56M
1-Year Return: +142.08%

Dividend and dates

Avg Volume: 85.32K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NRXS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−55.50%−11.99%+93.19%+31.28%

2023*202420252026*

Year	Return
2026 (partial year)	+31.28%
2025	+93.19%
2024	−11.99%
2023 (partial year)	−55.50%

As of September 4, 2026.

NRXS Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$3.57M	−$7.80M	−218.5%
2024	$2.69M	−$8.24M	−306.8%
2023	$2.46M	−$14.63M	−594.6%
2022	$2.68M	−$4.78M	−178.0%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$3.57M	$3.01M	−$7.83M	−$7.80M	−218.5%
2024	$2.69M	$2.32M	−$7.16M	−$8.24M	−306.8%
2023	$2.46M	$2.16M	−$6.66M	−$14.63M	−594.6%
2022	$2.68M	$2.39M	−$3.37M	−$4.78M	−178.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NRXS Valuation vs Biotechnology Median

Median of 656 stocks

Metric	NRXS	Biotechnology median	vs median
P/S ratio	14.08	15.26	8% below
Profit margin	−144.44%	0.00%	144.4 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NeurAxis, Inc. (NRXS) is capitalised at $74.84M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 24.

The most recent close on file for NRXS is $5.96, dated September 4, 2026. That is −$0.11 (−1.81%) against the previous close. The 52-week range on file runs from $2.21 to $9.33. The latest close sits 169.68% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $3.57M. Against the prior fiscal year total of $2.69M, that is a change of +32.89%. The same year closed with a net loss of $7.80M. Profit margin runs at −144.44%. That is 144.4 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.76.

Across the 4 fiscal years on file, revenue moves from $2.68M in 2022 to $3.57M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 14.08 times revenue. On price-to-sales that is 7.76% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +142.08%. Across 3 years the annualized return works out at +11.07%. Beta against the wider market is reported at 1.45. Daily returns over the trailing 3 years annualize to a volatility of 94.67%.

Growth & Income

The record shows no dividend for NRXS.

Across the complete calendar years on file, 2025 returned +93.19% and 2024 returned −11.99%. 2026 is still running; the price is +31.28% year to date.

Peer Comparison

NeurAxis, Inc. (NRXS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
NeurAxis, Inc.	NRXS	$74.84M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. NeurAxis, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About NeurAxis, Inc.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

Visit website →

NeurAxis, Inc. (NRXS) Stock Analysis